Table 1 Baseline characteristics of the study population

Sex F/M

14/109

9/64

5/45

Age (years)

57.94 ± 10.96

57.88 ± 10.03

58.02 ± 12.29

ALT (U/L)

30 (8–471.1)

27 (10–261)

35.5 (8–471.1)

AST (U/L)

47 (13–544)

38 (13–291)

52.5 (16–544)

TBiL (μmol/L)

18.3 (8.5–457)

17.8 (8.5–457.0)

20.0 (8.9–113.2)

ALB (g/L)

36.53 ± 4.91

36.98 ± 4.78

35.87 ± 5.06

D-Dimer (mg/L)

0.80 (0.10–15.61)

1.1 (0.27–15.61)

0.72 (0.10–13.95)

PTA (%)

80.62 ± 14.57

82.31 ± 12.92

78.14 ± 16.51

PLT (× 10⁹/L)

162.09 ± 99.10

161.96 ± 102.87

162.28 ± 94.37

AFP

441.06 (1.33–1210.0)

393.09 (1.33–1210.0)

511.09 (1.5–1210)

PIVKA-II (mAU/ml)

278.13 (1.6–75,000.00)

196.12 (12–75,000.00)

514.86 (1.6–75,000)

 YES/NO

105/18

30/5

75/13

 A

68

37

31

 B

55

36

19

 I

34

21

13

 II

51

30

21

 III

19

12

7

 IV

19

10

9

 A

12

9

3

 B

76

43

33

 C

35

21

14

 HBsAg (COI)

4578 (12.2–8657.0)

4512 (12.2–7542.0)

5221.5 (35–8657.0)

 Positive

55

32

23

 Negative

68

41

27

 HBV-DNA (IU/L)

7500.0 (0.0–4.16 × 10⁷)

5800.0 (0.0–4.16 × 10⁷)

21,750.0 (0.0–3.26 × 10⁷)